If You’re Managing High Cholesterol You Might Qualify For A New Clinical Research Opportunity

Heart disease, encompassing heart attacks and strokes, stands as the primary cause of mortality among adults in the United States. Alarmingly, it affects more Black adults than any other racial and ethnic demographic. A significant contributor to developing heart disease is high cholesterol, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C), often termed “bad cholesterol.”Excess LDL-C can lead to plaque formation in arterial walls, narrowing them and impeding blood flow. Untreated high levels elevate the risk of atherosclerosis, subsequently increasing the possibility of heart attacks or strokes. Adrelia Allen, Executive Director of Clinical Trial Patient Diversity at Merck, emphasized the necessity of inclusivity in clinical research to accurately evaluate treatments across all communities. Current studies are investigating a new oral PCSK9 inhibitor aimed at reducing LDL-C without injections. Participants aged 18 and older, meeting specified criteria, can join at no cost, with travel expenses reimbursed. Dr. Robert Blaustein from Merck encourages eligible individuals to consult their healthcare providers regarding these studies. For further details, visit coralreefstudies.com.